These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2353 related items for PubMed ID: 11464448

  • 1. Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin.
    Breuer HW.
    Curr Med Res Opin; 2001; 17(1):60-73. PubMed ID: 11464448
    [Abstract] [Full Text] [Related]

  • 2. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
    Strandberg TE, Feely J, Sigurdsson EL, DISCOVERY study group.
    Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
    [Abstract] [Full Text] [Related]

  • 3. Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid--a position paper developed by the European Consensus Panel on HDL-C.
    Chapman MJ, Assmann G, Fruchart JC, Shepherd J, Sirtori C, European Consensus Panel on HDL-C.
    Curr Med Res Opin; 2004 Aug; 20(8):1253-68. PubMed ID: 15324528
    [Abstract] [Full Text] [Related]

  • 4. Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes.
    Abdel-Maksoud M, Sazonov V, Gutkin SW, Hokanson JE.
    J Cardiovasc Pharmacol; 2008 Apr; 51(4):331-51. PubMed ID: 18427276
    [Abstract] [Full Text] [Related]

  • 5. Model-based simulation to explore the cost-effectiveness of following practice guidelines for triglyceride and low-density lipoprotein cholesterol control among patients with diabetes mellitus and mixed dyslipidemia.
    Sorensen SV, Frick KD, Wade A, Simko R, Burge R.
    Clin Ther; 2009 Apr; 31(4):862-79. PubMed ID: 19446159
    [Abstract] [Full Text] [Related]

  • 6. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ, Watson KE, Talbert RL.
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [Abstract] [Full Text] [Related]

  • 7. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR, Gandhi S, Blasetto J, Heien H, Sasane R, Nelson SP.
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [Abstract] [Full Text] [Related]

  • 8. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial.
    Pearson T, Denke M, McBride P, Battisti WP, Brady WE, Palmisano J.
    Am J Geriatr Pharmacother; 2005 Dec; 3(4):218-28. PubMed ID: 16503317
    [Abstract] [Full Text] [Related]

  • 9. Pharmacologic treatment of type 2 diabetic dyslipidemia.
    Moon YS, Kashyap ML.
    Pharmacotherapy; 2004 Dec; 24(12):1692-713. PubMed ID: 15585439
    [Abstract] [Full Text] [Related]

  • 10. Pharmacologic options for aggressive low-density lipoprotein cholesterol lowering: benefits versus risks.
    McKenney JM.
    Am J Cardiol; 2005 Aug 22; 96(4A):60E-66E. PubMed ID: 16098846
    [Abstract] [Full Text] [Related]

  • 11. Combination therapy with statins and omega-3 fatty acids.
    Nambi V, Ballantyne CM.
    Am J Cardiol; 2006 Aug 21; 98(4A):34i-38i. PubMed ID: 16919515
    [Abstract] [Full Text] [Related]

  • 12. Apolipoprotein modifying effects of statins and fibrate in various age groups of coronary artery disease patients.
    Sharma R, Mahajan M, Singh B, Bal BS, Kant R.
    J Indian Med Assoc; 2006 Sep 21; 104(9):492-4, 496, 498. PubMed ID: 17388006
    [Abstract] [Full Text] [Related]

  • 13. Advances in drug treatment of dyslipidemia: focus on atorvastatin.
    Davignon J.
    Can J Cardiol; 1998 May 21; 14 Suppl B():28B-38B. PubMed ID: 9627539
    [Abstract] [Full Text] [Related]

  • 14. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin.
    Stein E, Stender S, Mata P, Sager P, Ponsonnet D, Melani L, Lipka L, Suresh R, Maccubbin D, Veltri E, Ezetimibe Study Group.
    Am Heart J; 2004 Sep 21; 148(3):447-55. PubMed ID: 15389231
    [Abstract] [Full Text] [Related]

  • 15. A population-based treat-to-target pharmacoeconomic analysis of HMG-CoA reductase inhibitors in hypercholesterolemia.
    Hilleman DE, Phillips JO, Mohiuddin SM, Ryschon KL, Pedersen CA.
    Clin Ther; 1999 Mar 21; 21(3):536-62. PubMed ID: 10321422
    [Abstract] [Full Text] [Related]

  • 16. Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy.
    Fazio S.
    Clin Ther; 2008 Feb 21; 30(2):294-306. PubMed ID: 18343268
    [Abstract] [Full Text] [Related]

  • 17. Management of dyslipidemia in the high-risk patient.
    Stein EA.
    Am Heart J; 2002 Dec 21; 144(6 Suppl):S43-50. PubMed ID: 12486415
    [Abstract] [Full Text] [Related]

  • 18. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study.
    Koren MJ, Hunninghake DB, ALLIANCE Investigators.
    J Am Coll Cardiol; 2004 Nov 02; 44(9):1772-9. PubMed ID: 15519006
    [Abstract] [Full Text] [Related]

  • 19. Statins and diabetes.
    Carmena R, Betteridge DJ.
    Semin Vasc Med; 2004 Nov 02; 4(4):321-32. PubMed ID: 15861314
    [Abstract] [Full Text] [Related]

  • 20. The association between fibrate use, change in high-density lipoprotein cholesterol, and the risk of cardiovascular disease: a retrospective chart review involving up to 8 years of follow-up.
    Nichols GA, Koro CE, Chan W, Bowlin SJ, Sprecher DL.
    Clin Ther; 2006 Feb 02; 28(2):243-50. PubMed ID: 16678645
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 118.